A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression

Nordic Journal of Psychiatry

Volumn 66, Issue 3, 2012, Pages 147-154

  Martiny, Klaus ^a   Lunde, Marianne ^b   Bech, Per ^b   Plenge, Per ^a  

^a Rigshospitalet   (Denmark)

^b Psychiatric Research Unit   (Denmark)

Author keywords

Depressive disorder; Drug monitoring; Pindolol; Randomized controlled trial; Venlafaxine

Indexed keywords

DESVENLAFAXINE; N DESMETHYLVENLAFAXINE; PINDOLOL; PLACEBO; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PINDOLOL; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862082116     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2012.674553     Document Type: Article

References (26)

1. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51. (Pubitemid 24081512)
2. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996;19:378-83. (Pubitemid 26270513)
3. Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: A systematic review. J Psychopharmacol 2010;24:513-20.
4. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: A meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 2004;79:137-47. (Pubitemid 38340537)
5. Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry. 2001;158:2080-2. (Pubitemid 33104122)
6. Rabiner EA, Bhagwagar Z, Gunn RN, Cowen PJ, Grasby PM. Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: Effect of treatment or an endophenotype of depression? Neuropsychopharmacology 2004;29:1688-98. (Pubitemid 39157360)
7. Plenge P, Mellerup ET. Pindolol and the acceleration of the antidepressant response. J Affect Disord 2003;75:285-9. (Pubitemid 36860032)
8. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou- Gharbia M, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65. (Pubitemid 44061240)
9. Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J Clin Psychopharmacol 2009;29:383-6.
10. Schmid B, Bircher J, Preisig R, Kü pfer A. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O -demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38: 618-24. (Pubitemid 16124372)
11. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-22. (Pubitemid 28150857)
12. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey J, Bertschy G. Time course of clinical response to venlafaxine: Relevance of plasma level and chirality. Eur J Clin Pharmacol 2004;59:883-91. (Pubitemid 38333679)
13. EMEA 1997. Note for guidance on Good Clinical Practice (CPMP/ ICH/135/95). The European Agency for the Evaluation of Medicinal Products, London.
14. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry 1998;59 Suppl 20:22-33; quiz 34-57. (Pubitemid 29001829)
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC American Psychiatric Association; 1994.
16. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand 1986;326:1-37.
17. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, et al. The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981;63:290-9. (Pubitemid 11137960)
18. O ' Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1997;95:379-84.
19. Bech P. The Bech- Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: A 20-year review of its use as outcome measure. Acta Psychiatr Scand 2002;106:252-64.
20. Licht RW, Qvitzau S, Allerup P, Bech P. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; Is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005;111:144-9. (Pubitemid 40293182)
21. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specifi city of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. JAffect Disord 2001;66:159-64. (Pubitemid 32907521)
22. Bech P. Measuring the dimensions of psychological general wellbeing by the WHO-5. QoL Newsletter 2004;32:15-16.
23. L ingjæ r de O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987:334:1-100. (Pubitemid 17115352)
24. Brown H,Prescott R.Applied mixed models in medicine.Chichester: Wiley;1999.
25. Shams ME, Arneth B, Hiemke C, Dragicevic A, Mü ller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Clin Pharm Ther 2006;31:493-502. (Pubitemid 44337299)
26. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR * D) trial: A review. Can J Psychiatry 2010;55:126-35.